Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
29
Recruiting, any sponsor type, condition "endometriosis"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed182
29 trials
Showing 1 to 25, recently updated first.
Christiana Care Health ServicesAcademic, hospital or other
NCT07664956 · 36 participants (planned) · Start Sep 1, 2026 · Primary completion May 1, 2027
Drug: Cyclobenzaprine · For: Minimally Invasive Surgical Procedures; Abnormal Uterine Bleeding, Unspecified; Adenomyosis of Uterus and 6 more
Sites: Newark, Delaware
Andrew ZakhariAcademic, hospital or other
NCT05837624 · 21 participants (planned) · Start Dec 3, 2024 · Primary completion Jul 2027
Drug: Estetrol/Drospirenone · For: Ovarian Endometrioma; Endometrioma
Sites: Montreal, Canada
Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.Industry
NCT07755956 · 20 participants (planned) · Start Oct 31, 2026 · Primary completion Mar 31, 2027
Drug: HHK001; Enantone · For: Endometriosis
Sites: Changsha, China; Suzhou, China
Bio Meds Pharmaceutica LtdaIndustry
NCT06543550 · 70 participants (planned) · Start Jul 30, 2024 · Primary completion Mar 2027
Drug: Implantable gestrinone; Oral Dienogest · For: Endometriosis
Sites: Campina Grande, Brazil; Rio de Janeiro, Brazil; São José dos Campos, Brazil · 4 sites in all
- Stellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic SurgeryPivotal-lookingRecruiting
Catherin ZhangAcademic, hospital or other
NCT07860203 · 100 participants (planned) · Start Oct 2026 · Primary completion Dec 2026
Drug: DEX 0.2 μg/kg/h.; 0.9% Sodium Chloride (Placebo) · For: Uterine Fibroids (Leiomyoma); Adenomyosis of Uterus; Endometriosis and 3 more
Sites: Huai'an, China
- Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated PainPivotal-lookingRecruiting
Hope Medicine (Nanjing) Co., LtdIndustry
NCT07318688 · 540 participants (planned) · Start Jan 29, 2026 · Primary completion Mar 1, 2028
Drug: HMI-115; Placebo · For: Endometriosis
Sites: Beijing, China; Nanning, China; Suzhu, China · 5 sites in all
Penn State UniversityAcademic, hospital or other
NCT05069740 · 24 participants (planned) · Start Jan 1, 2022 · Primary completion Dec 31, 2026
Drug: Salsalate Pill; Placebo · For: Endometriosis
Sites: University Park, Pennsylvania
Staci Gruber, Ph.D.Academic, hospital or other
NCT07728695 · 60 participants (planned) · Start Sep 2026 · Primary completion Jan 2029
Drug: Custom-formulated, high-CBD study product; Placebo · For: Endometriosis; Adenomyosis; Chronic Pelvic Inflammatory Disease
Sites: Belmont, Massachusetts
- Endometriosis and MigraineRecruiting
Washington University School of MedicineAcademic, hospital or other
NCT06785129 · 120 participants (planned) · Start Feb 12, 2025 · Primary completion Jan 1, 2028
Drug: Hormonal assessment · For: Migraine; Endometriosis
Sites: St Louis, Missouri
- Ultra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating EndometriosisPivotal-lookingRecruiting
Li-jun DingAcademic, hospital or other
NCT07696351 · 120 participants (planned) · Start Aug 1, 2025 · Primary completion Dec 31, 2026
Drug: Triptorelin (GnRH agonists) · For: Deep Infiltrating Endometriosis (DIE); Infertility
Sites: Nanjing, China
University of EdinburghAcademic, hospital or other
NCT07240883 · 1,000 participants (planned) · Start Dec 5, 2025 · Primary completion Dec 31, 2030
Drug: Sample and data collection · For: Endometriosis
Sites: Edinburgh, United Kingdom
- The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled TrialPivotal-lookingRecruiting
Main Line HealthAcademic, hospital or other
NCT06439524 · 110 participants (planned) · Start Aug 15, 2024 · Primary completion Jun 30, 2028
Drug: 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate · For: Endometriosis
Sites: Wynnewood, Pennsylvania
University of EdinburghAcademic, hospital or other
NCT07523997 · 30 participants (planned) · Start Apr 8, 2026 · Primary completion Apr 1, 2027
Drug: Buscopan 20 MG/ML Injectable Solution · For: Endometriosis
Sites: Edinburgh, United Kingdom
- Pesticides and Infertility: Oxidative Stress Via Circulating Cell-free DNA and Gut/Genital Microbiome Signatures in Women With EndometriosisPivotal-lookingRecruiting
Centre Hospitalier Universitaire, AmiensAcademic, hospital or other
NCT07471373 · 160 participants (planned) · Start Feb 27, 2026 · Primary completion Feb 2028
Drug: Circulating DNA analysis; Vaginal microbiota analysis and 3 more · For: Endometriosis; Infertility; Female Fertility and 7 more
Sites: Salouël, France
University Hospital, GenevaAcademic, hospital or other
NCT07173127 · 30 participants (planned) · Start Sep 30, 2025 · Primary completion Dec 30, 2026
Drug: Ryeqo treatment · For: Uterine Fibroid
Sites: Geneva, Switzerland
- Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic PainPivotal-lookingRecruiting
University of MichiganAcademic, hospital or other
NCT07100782 · 130 participants (planned) · Start Dec 8, 2025 · Primary completion Aug 2028
Drug: Relugolix CT · For: Endometriosis; Pelvic Pain
Sites: Ann Arbor, Michigan
- Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or AdenomyosisPivotal-lookingRecruiting
Hopital FochAcademic, hospital or other
NCT04356664 · 180 participants (planned) · Start Mar 18, 2021 · Primary completion Jun 18, 2026
Drug: GnRH agonist · For: Endometriosis; Adenomyosis; Infertility, Female
Sites: Suresnes, France
- The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)Pivotal-lookingRecruiting
Centre Hospitalier Universitaire VaudoisAcademic, hospital or other
NCT05726786 · 232 participants (planned) · Start Apr 10, 2023 · Primary completion Aug 2026
Drug: Immunonutrition · For: Bladder Cancer; Interstitial Cystitis; Painful Bladder Syndrome and 4 more
Sites: Lausanne, Switzerland; Bern, Switzerland; Geneva, Switzerland · 4 sites in all
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT04481321 · 5,300 participants (planned) · Start May 2006 · Primary completion Jun 2040
Drug: Biological/Vaccine · For: Endometriosis; Adenomyosis
Sites: Paris, France
University Hospital, Clermont-FerrandAcademic, hospital or other
NCT06426316 · 396 participants (planned) · Start Jun 2, 2025 · Primary completion Apr 30, 2027
Drug: Blood test · For: Migraine Disorders; Pain; Autoimmune Diseases and 5 more
Sites: Clermont-Ferrand, France
- Clinical Study to Compare Efficacy and Safety of Indinol Forto® 200 mg Capsules and Visanne 2 mg Tablets in Treatment of EndometriosisPivotal-lookingRecruiting
AlceaAcademic, hospital or other
NCT07164183 · 290 participants (planned) · Start Sep 11, 2025 · Primary completion Oct 2026
Drug: Indole-3-carbinol; Dienogest · For: Endometriosis
Sites: Kazan', Russia; Moscow, Russia; Rostov-on-Don, Russia · 8 sites in all
Sumitomo Pharma Switzerland GmbHIndustry
NCT05739123 · 728 participants (planned) · Start May 8, 2023 · Primary completion May 2033
Drug: Relugolix-Containing Product · For: Pregnancy Related; Pregnancy Complications; Pregnancy, High Risk
Sites: Wilmington, North Carolina
- A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated PainPivotal-lookingRecruiting
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT06963177 · 200 participants (planned) · Start May 26, 2025 · Primary completion May 15, 2028
Drug: GenSci048; Placebo · For: Endometriosis-related Pain
Sites: Beijing, China
- A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or EndometriosisPivotal-lookingRecruiting
Sumitomo Pharma Switzerland GmbHIndustry
NCT05862272 · 1,000 participants (planned) · Start Aug 14, 2023 · Primary completion Jul 2029
Drug: Relugolix Combination Tablet · For: Uterine Fibroids; Endometriosis
Sites: Mobile, Alabama; Chandler, Arizona; Mesa, Arizona · 120 sites in all
- Endometriosis and Pain Treatment by Intraoperative Administration of Low-dose KetaminePivotal-lookingRecruiting
Insel Gruppe AG, University Hospital BernAcademic, hospital or other
NCT06951802 · 118 participants (planned) · Start Dec 3, 2024 · Primary completion Jun 30, 2025
Drug: Ketamine; Propofol · For: Endometriosis
Sites: Bern, Switzerland
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.